Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

ARIAD Pharmaceuticals Inc

+ Add to Watchlist

APS:GR

8.251 EUR 0.214 2.53%

As of 09:03:42 ET on 04/17/2015.

Snapshot for ARIAD Pharmaceuticals Inc (APS)

Open: 8.367 Day's Range: 8.210 - 8.733 Volume: 4,398
Previous Close: 8.465 52wk Range: 3.623 - 8.733 1-Yr Rtn: +57.07%

Stock Chart for APS

No chart data available.
  • APS:GR 8.216
  • 1D
  • 1M
  • 1Y
8.465
Interactive APS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for APS

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -1.0520
Est. PEG Ratio -
Market Cap (M EUR) 1,547.33
Shares Outstanding (M) 187.53
30 Day Average Volume 5,972
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for APS

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for APS

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. The Company's approach to structure-based drug design has led to several molecularly targeted medicines for drug-resistant or difficult-to-treat cancers.

Harvey J BergerChairman/President/CEOTimothy P ClacksonChief Scientific Ofcr/Pres:R&D
Edward M FitzgeraldExec VP/CFO/TreasurerMartin J Duvall "Marty"Exec VP/Chief Commercial Ofcr
More Company Profile & Key Executives for APS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil